INTRODUCTION
Pre-operative anxiety has been described as a subjective feeling of apprehension, fear, and nervousness. [1] Many pharmacological and non-pharmacological methods have been used to allay anxiety in the pre-operative period. Anticonvulsants such as gabapentin and pregabalin are used effectively to attenuate pre-operative anxiety. Levetiracetam that is a novel antiepileptic drug has also shown anxiolysis property in various studies. [2, 3] To date, no clinical study has evaluated the efficacy of levetiracetam in reducing pre-operative anxiety. We conducted this study to assess the effects of levetiracetam on attenuating pre-operative anxiety.
METHODS
This prospective, randomized, double-blind, and placebo-controlled study was carried out after taking approval by Local Ethical Committee and written informed consent from the patients. The study protocol was registered prospectively at Clinical Trial Registry of India (CTRI/2014/01/004323). A total 102 patients, aged 18-70 years, of American Society of Anesthesiologists physical status I and II, who were scheduled to undergo laparoscopic cholecystectomy, were included in the study. Exclusion criteria were: Body mass index <19 and >35 kg/m 2 known sensitivity to study drugs, inability to tolerate oral medication and understand visual analogue scale score (VAS) significant respiratory, cardiac, renal or hepatic dysfunction, patients on chronic pain medication, anticonvulsant or antidepressant drugs.
A resident doctor who was not participating in the trial prepared the randomization sequence using 'research randomizer' software (http://www.randomizer.org/) before starting the study.
Pre-operative anxiety was assessed using VAS score on which 0 indicated 'no anxiety' and 100 represented 'worst imaginable anxiety'.
The patients were randomly assigned into two groups. Group 1 (control) received placebo (iron) tablet that was looking similar to levetiracetam tablet, Group 2 (levetiracetam) received tablet levetiracetam 500 mg. (Leveroxa ® , Ranbaxy). After assessing base line anxiety in the ward, one nurse who was not part of the study gave one table to each patient in sequentially numbered, sealed, opaque envelops. Patients, investigators, and outcome assessor were not aware of the type of medication. Anxiety was assessed again in the pre-operative holding area and in the operation theatre just before induction of anaesthesia by a nurse who did not participate in the study.
Other anxiolytic pre-medications were omitted. All patients received same standardized general anaesthesia. The primary outcome measure of the study was the level of pre-operative anxiety in term of VAS score, and incidence of any side effects as secondary outcomes. Adverse effects that is, headache, nausea, blurred vision, vomiting, respiratory depression, etc., were noted.
The superiority sample size calculation was done on the basis of VAS score for anxiety assessment as reported in previous published literature. [4] Assuming that levetiracetam would decrease VAS score by 30%, at significance level of α = 0.05 and β = 0.10,46 patients patients were needed to be enrolled in each group. We enrolled 51 patients in each group to minimize the effect of any missing data.
The distribution of data was determined by Kolmogorov-Smirnov analysis and Bartlellet's test. The groups were compared with unpaired Student's t-test, unpaired t-test with Welch correction, and Mann-Whitney U-test. Z-test was done to detect a significant difference among proportion. Data were presented as mean ± SD, median ± interquartile range, numbers (n), and percentages (%). The package SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and GraphPad instate were used for statistical analysis. P < 0.05 was considered significant.
RESULTS
Total 113 patients were assessed for eligibility, out of which 102 patients were randomized either to get study drug or placebo. Patients in both the groups were comparable in regards to demographic variables and baseline anxiety. There was no significant difference in the level of pre-operative anxiety between the groups [ Figure 1 ]. Two patients in the control group had pre-mature ventricular contractions which subsided within a minute without any medications. One patient in Levetiracetam group developed bronchospasm which was treated with 400 µg of inhaled salbutamol.
DISCUSSION
The precise mechanism of anxiolysis by levetiracetam is yet to be elucidated. Unlike other anticonvulsants, levetiracetam does not bind with gamma-aminobutyric acid (GABA) receptors. But it can facilitate the action of GABA by altering its metabolism or transportation. [5] It may also cause anxiolysis by inhibiting excitatory neurotransmitters such as glutamine and glutamate. [6] After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration attained after 1½ h, and its bioavailability is more than 95%. [7] One study on refractory anxiety disorder found that levetiracetam at mean (SD) dose of 1969 ± 819 mg/day was an effective anxiolytic agent. [2] This finding was supported by a study of social anxiety disorder where levetiracetam was flexibly titrated to 3000 mg/day. [3] Our study failed to show anxiolysis efficacy of levetiracetam in the setting of pre-operative anxiety. Similar to our study, one multi centric study found that levetiracetam was not effective in social anxiety disorder; the lower doses may be responsible. [8] Present study is the first clinical trial that examined the pre-operative anxiolysis efficacy of levetiracetam. The study has some limitations. One may criticize that we used VAS score to assess anxiety which is not the gold standard. Inadequate dose of levetiracetam was a major limitation of our study. Other studies that evaluated anxiolysis property of levetiracetam started with smaller dose that is, 250 mg, then it was gradually increased over weeks to a higher dose in an attempt to avoid any untoward effect and increase tolerability of medication. We avoided the use of higher dose that may possibly increase the incidence of side effects.
CONCLUSION
A single dose of levetiracetam at 500 mg dose was not useful in decreasing pre-operative anxiety. 
INTRODUCTION
Neurologic injuries secondary to central neuraxial block are extremely rare. [1] Aetiology could be traumatic or non-traumatic. The anatomical site of damage could be the spinal cord, nerve roots or spinal vasculature. Mechanical, ischaemic, and neurotoxic insults have an additional contributory effect. [2] We present a case of acute onset paraplegia following a subarachnoid block in an elderly female and discuss the aetiology, differential diagnosis, prognosis and treatment.
CASE REPORT
An 85-year-old female with fracture neck of femur and no other co-morbidity was scheduled for a cemented hemi-arthroplasty. Her height was 4 feet and 5 inches, and her weight was 35 kg. Her baseline investigations were normal, but examination of the spine revealed dorso lumbar kyphoscoliosis.
Standard monitors were attached including electrocardiogram, pulse oximetry and non-invasive blood pressure. Combined spinal epidural anaesthesia was planned but difficulty was anticipated due to the spinal deformity. An 18 gauge Tuohy needle was inserted in the midline at L 3 -L 4 intervertebral space with the patient in the sitting position. Technique used was loss of resistance to air but this could not be appreciated by the anaesthesiologist and dural puncture occurred during third attempt; in the first two attempts, the needle was hitting the lamina of the spinous processes. A volume of 1.8 mL 0.5% hyperbaric bupivacaine along with 25 µg fentanyl was administered intrathecally.A level of the block till T10 was achieved; intraoperative vitals were stable. Duration of surgery was 2 h. Fluids administered included the maintenance volume calculatetd by 4:2:1 rule and additional 1 L of crystalloids, followed by 2 L in the next 24 h. She was monitored for post-dural puncture headache for the next 48 h. The post-operative pain was managed by tramadol. She developed fever 9 h after surgery. She also complained of tingling and weakness in both lower limbs. She was restless and anxious during the neurological examination. There was absence of deep tendon reflexes (plantar, ankle and knee), muscle weakness (Grade 1/5 for flexors and extensors of hip and knee), decreased tone and absent sensation to pain, touch and vibration in bilateral lower limbs and a diagnosis of a lower motor neuron type of paralysis with sensory involvement was established. The neurological examination was repeated after 12, 24 and 48 h. By the 2 nd day, there was some improvement in motor power (Grade 2/5 for flexors and extensors of hip and knee). There was no bladder or bowel involvement (assessed on day 1 and day 2).
